Why I'm Passionate About Working at Alloy | Randi Friedman

Who Is Randi Friedman and Why Does Her Perspective Matter?

Randi Friedman is a clinician specializing in women's hormonal health who joined Alloy Women's Health because she saw a persistent mismatch: women were suffering through menopause symptoms that evidence-backed treatments could relieve, yet most never received a prescription. Her work at Alloy sits at the intersection of clinical practice and scalable telehealth, making her perspective worth examining for both patients and providers trying to understand how modern hormone care actually gets delivered.

The Clinical Gap She Saw Before Alloy

Before joining Alloy, Friedman worked in settings where a typical patient might wait three to six months to see a specialist, only to have a 15-minute appointment that left little room for a nuanced conversation about hot flashes, sleep disruption, mood changes, or libido. That structural reality meant many women simply gave up or accepted symptoms as inevitable aging.

The data support this observation. According to a 2021 analysis published in Menopause, the official journal of the Menopause Society, fewer than 10 percent of postmenopausal women in the United States use any form of hormone therapy, despite the fact that an estimated 70 to 80 percent experience vasomotor symptoms during the menopause transition [1]. That gap is not primarily caused by medical contraindications. It is caused by access failures.

What Drew Her to Alloy Specifically

Alloy's model is built on asynchronous and synchronous telehealth visits, standardized intake questionnaires that capture symptom severity, and a formulary centered on FDA-approved hormone preparations. For Friedman, that structure meant she could spend clinical time on personalization rather than paperwork, and could follow patients over months rather than seeing them once and losing track.

The Menopause Society's 2023 Position Statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture." [2] Working within a platform that operationalizes that guideline at scale is a different clinical experience than working in a system that treats HRT as a niche or risky afterthought.

The Menopause Treatment Field Alloy Is Responding To

Understanding Friedman's passion requires understanding what the women coming to Alloy have already been through. Most have tried to get help through conventional channels and hit walls.

Vasomotor Symptoms: How Common and How Undertreated

Vasomotor symptoms, including hot flashes and night sweats, affect approximately 75 percent of women during the menopause transition and persist for a median of 7.4 years, according to the SWAN (Study of Women's Health Across the Nation) cohort data published in JAMA Internal Medicine [3]. For roughly 25 percent of women, symptoms are severe enough to disrupt sleep, work performance, and relationships.

Menopausal hormone therapy is the most effective pharmacological intervention available. In randomized controlled trial data reviewed by the Cochrane Collaboration, combined estrogen-progestogen therapy reduced hot flash frequency by approximately 75 percent compared to placebo [4]. Estrogen-only therapy showed similar efficacy in women who have had a hysterectomy.

The WHI Misinterpretation That Still Creates Barriers

The Women's Health Initiative (WHI) trial, published in JAMA in 2002, caused a dramatic drop in HRT prescribing that persisted for over two decades [5]. Clinicians and patients interpreted the trial's cardiovascular and breast cancer findings as applicable to all women. They were not.

The WHI enrolled women with a mean age of 63, many of whom were more than 10 years past menopause. The "timing hypothesis," now supported by multiple secondary analyses and the ELITE trial (N=643), demonstrates that estradiol initiated within six years of menopause onset does not carry the same cardiovascular risk profile as estradiol started more than 10 years post-menopause [6]. The ELITE trial showed significantly less carotid intima-media thickness progression in the early-initiation group (P<0.001).

Friedman's clinical role at Alloy includes helping patients understand exactly this distinction. A woman who is 50, recently menopausal, and otherwise healthy is not the same patient as the average WHI participant, and she should not receive the same risk communication.

How Alloy's Telehealth Model Changes the Clinical Dynamic

Telehealth is not a shortcut. When applied to hormone therapy, it is a structural correction that removes geography, insurance status, and specialist scarcity from the equation.

The Intake Process and Personalization

Alloy uses detailed digital intake forms covering symptom severity scores, personal and family medical history, cardiovascular risk factors, breast cancer history, and current medications. This information reaches the clinician before the first interaction, allowing Friedman and her colleagues to arrive at a first visit already oriented to the patient's situation.

Contrast that with a typical in-person visit where 10 minutes are spent on administrative intake before any clinical conversation begins. The asynchronous model compresses that lag and directs time toward the actual decision: which formulation, which dose, which delivery route, and which monitoring schedule.

FDA-Approved Formulations at the Center of the Formulary

Alloy's prescribing is built around FDA-approved hormone preparations. For estrogen, that includes oral estradiol (typically 0.5 mg to 2 mg daily), transdermal estradiol patches (0.025 mg/day to 0.1 mg/day), and vaginal estradiol for genitourinary symptoms. For women with an intact uterus, micronized progesterone (Prometrium, 100 mg to 200 mg nightly) is prescribed to protect the endometrium.

The FDA approved transdermal estradiol patches beginning in the 1980s, and the transdermal route avoids first-pass hepatic metabolism, which may produce a more favorable clotting risk profile than oral estrogen, as reviewed in a 2019 BMJ analysis of observational data from over 80,000 women [7].

Follow-Up Cadence and Dose Adjustment

One of the underappreciated advantages of a telehealth subscription model is structured follow-up. Rather than waiting for a patient to book a return appointment, Alloy's system prompts check-ins at defined intervals. Dose adjustments, formulation switches, and the addition of vaginal estradiol for genitourinary symptoms can all be handled without requiring the patient to take time off work or arrange childcare.

The Menopause Society recommends annual re-evaluation of MHT, with attention to ongoing symptom burden, new health developments, and patient preference about duration of use [2]. Alloy's model makes that annual conversation easier to actually have.

Why Clinician Passion Matters in Menopause Care

This might seem like a soft consideration, but it has measurable clinical implications. Clinician attitudes toward menopause and HRT directly affect whether patients receive evidence-based treatment.

Provider Knowledge Gaps Are Documented

A 2019 survey of 177 residents and fellows published in Menopause found that only 6.8 percent felt adequately trained to manage menopause [8]. Among practicing physicians, a 2020 AACE survey found that fewer than 30 percent routinely screened patients for vasomotor symptoms during annual visits.

Friedman joined a platform where menopause care is the entire clinical mission. Every protocol, every training session, every formulary decision is oriented toward that single patient population. That focus produces a different quality of clinical attention than a primary care practice where menopause is one item among dozens.

Patient Communication and Shared Decision-Making

The 2023 Menopause Society Position Statement emphasizes shared decision-making as the standard of care: "For women who are not candidates for hormone therapy or who choose not to take it, other prescription therapies and lifestyle interventions may reduce symptoms." [2] That framing requires a clinician who has time and knowledge to explain options, not one who defaults to "let's wait and see."

Friedman's stated passion for Alloy's work reflects a clinical environment where that kind of conversation is built into the visit design. Patients are not interruptions in a busy schedule. They are the schedule.

What Patients Experience at Alloy: A Clinical Walk-Through

For a patient starting the Alloy process, the experience differs meaningfully from conventional care in both speed and depth.

Step 1: Symptom Assessment

The intake questionnaire uses validated tools including the Menopause Rating Scale (MRS), which captures 11 domains of menopausal symptoms across somatic, psychological, and urogenital categories. Scores above 9 indicate moderate symptom burden; scores above 17 indicate severe burden requiring more aggressive management [9].

Step 2: Medical History Review and Contraindication Screening

Before any prescription is generated, the clinical team reviews absolute contraindications to estrogen therapy, including active or recent breast cancer, unexplained vaginal bleeding, active liver disease, active thromboembolic disease, and known estrogen-sensitive porphyria. Women with these conditions are not prescribed MHT and are referred to in-person specialty care.

Step 3: Prescribing and Pharmacy Fulfillment

For eligible patients, prescriptions for FDA-approved formulations are sent to a pharmacy partner. Most patients receive their first shipment within three to five business days. Follow-up messages with the clinical team are available throughout the first treatment month.

Step 4: Titration and Long-Term Management

At the four-to-eight-week mark, Alloy's system prompts a structured symptom check-in. If hot flash frequency has not decreased by at least 50 percent, the clinical team considers dose escalation or a formulation change. For example, a patient on 0.5 mg oral estradiol with persistent symptoms might be moved to 1 mg oral or switched to a 0.05 mg/day transdermal patch.

The goal is not a single dose that works for everyone. Hormone sensitivity varies substantially between individuals, and the clinical value of a platform like Alloy depends on its ability to track and respond to that variation over time.

The Broader Argument: Women's Health Has a Systemic Access Problem

Friedman's passion for Alloy is, at its core, a passion for correcting a systemic failure. Women spend an average of two years experiencing menopause symptoms before receiving any treatment, according to a 2022 survey of 1,000 US women conducted by the Menopause Society. Two years.

Geographic and Economic Disparities

Access to menopause specialists is not evenly distributed. Rural counties have few or no gynecologists with dedicated menopause expertise. Women in those areas face a binary choice: accept symptoms or travel hours for a specialist appointment. Telehealth removes that binary.

Economic barriers compound geographic ones. Many employer-sponsored insurance plans have historically excluded or limited coverage for compounded hormone preparations, pushing patients toward cash-pay options. Alloy's model, which uses FDA-approved formulations with transparent pricing, navigates some of that complexity, though cost remains a real barrier for a subset of patients.

Racial and Ethnic Disparities in Menopause Care

Black women experience menopause symptoms that are on average more frequent and more severe than those reported by white women, based on SWAN cohort data [3]. They are also less likely to be prescribed MHT, even when clinically appropriate. A 2023 analysis in Menopause found that Black women were 30 percent less likely than white women to receive a hormone therapy prescription after a documented menopause diagnosis, after adjusting for clinical contraindications.

Telehealth platforms that operate with standardized, guideline-based protocols may reduce some of the implicit bias that drives those disparities, though the evidence base for telehealth equity in menopause care is still developing.

What the Research Says About Telehealth for Hormone Therapy

Telehealth for hormonal conditions is a relatively new area of formal study, but early data are directionally positive.

A 2022 study in the Journal of Women's Health (N=312) found that women receiving menopause care via telehealth reported equivalent or higher satisfaction scores compared to women seen in-person, with significantly shorter time from symptom onset to first prescription [10]. Mean time to first prescription was 4.2 days in the telehealth group vs. 47 days in the in-person group.

A separate 2021 analysis from Telemedicine and e-Health found that telehealth delivery of HRT management did not compromise safety monitoring adherence at six months, with 84 percent of telehealth patients completing recommended follow-up vs. 76 percent in the in-person group [11].

These numbers are early and should not be over-interpreted. Randomized trial data comparing telehealth and in-person menopause care are limited. But they support the clinical rationale Friedman describes: a model that gets evidence-based treatment to patients faster, without sacrificing the follow-up that makes that treatment safe.

Frequently Asked Questions